Scientific Information

WELCOME AND INTRODUCTION

Tore Curstedt, Stockholm, Sweden; Henry L. Halliday, Belfast, United Kingdom

12th BENGT ROBERTSON MEMORIAL LECTURE IMPROVING THE EFFICIENCY AND IMPACT OF CLINICAL RESEARCH: A GAME CHANGER FOR 21ST CENTURY NEONATOLOGY

Neena Modi, London, United Kingdom

IMPROVING GLOBAL NEWBORN SURVIVAL: BUILDING UPON HELPING BABIES BREATHE

Susan Niermeyer, Denver, United States

Discussion

COFFEE BREAK

Chairpersons:
Corrado Moretti, Rome, Italy
Rangasamy Ramanathan, Los Angeles, United States

OPTIMAL VENTILATION AND SURFACTANT TREATMENT IN RESOURCE LIMITED COUNTRIES

Johan Smith, Cape Town, South Africa

NON-VENTILATORY STRATEGIES, A CRITICAL UPDATE

Charles-Christoph Roehr, Oxford, United Kingdom

Discussion

LUNCH

POSTER PRESENTATIONS

Chairpersons:
Sture Andersson, Helsinki, Finland
Gianluca Lista, Milan, Italy

THE EFFECTS OF ANTENATAL CORTICOSTEROID ADMINISTRATION ON PREMA-TURITY-RELATED OUTCOMES ACCORDING TO PRESENCE OF MATERNAL HIS-TOLOGIC CHORIOAMNIONITIS IN INFANTS <30 WEEKS GESTATIONAL AGE

O. Ertekin, Ankara, Turkey

EARLY USE OF AZITHROMYCIN ON THE PREVENTION OF VENTILATION-INDUCED LUNG INJURY BY RELEASE OF PROINFLAMATORY CYTOKINES: DOU-BLE-BLIND RANDOMIZED CLINICAL TRIAL

R. C. Silveira, Porto Alegre, Brazil

CAN LUNG ULTRASOUND GUIDE AND MONITOR SURFACTANT ADMINISTRA-TION? PRELIMINARY DATA FROM A MULTI CENTER PROTOCOL

F. Raimondi, Naples, Italy

DIRECT EFFECT OF CAFFEINE ON DIAPHRAGMATIC MUSCLES

G. Kayki, Ankara, Turkey

ACUTE KIDNEY INJURY IN VERY LOW BIRTH WEIGHT PRETERM USING NEONA-TAL KDIGO DEFINITION: UTILITY OF URINE OUTPUT

M. Saint-Faust, Geneva, Switzerland

HYPEROXIA CAN RESULT A SHIFT IN BRAIN ENERGY METABOLISM FROM GLY-COLYSIS TO PENTOSE PHOSPHATE PATHWAY

A. Kumral, Izmir, Turkey

Chairpersons:
Virgilio Carnielli, Ancona, Italy
Johan Smith, Cape Town, South Africa

DETERMINING THE HAEMODYNAMIC SIGNIFICANCE OF A PATENT DUCTUS ARTERIOSUS USING ECHOCARDIOGRAPHY: DO WE HAVE ALL THE ANSWERS?

Afif El-Khuffash, Dublin, Ireland

FREE COMMUNICATIONS

EFFECT OF SYNTHETIC SURFACTANT WITH SP-B AND SP-C ANALOGUES (CHF5633) ON LUNG FUNCTION IN A MODEL OF SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME

P. Mikolka, Martin, Slovakia

INCREASED RESISTANCE TOWARDS SURFACTANT INACTIVATION IN LARGE SURFACTANT AGGREGATES OF NEAR TERM RABBITS WITH NEONATAL E.COLI OR GBS PNEUMONIA FOLLOWING TREATMENT WITH NEW SYNTHETIC AND MODIFIED PORCINE SURFACTANT

G. Stichtenoth, Lübeck, Germany

LONG-TERM OUTCOME OF LESS INVASIVE SURFACTANT ADMINISTRATION (LI-SA) – FOLLOW-UP OF THE RANDOMIZED CONTROLLED NINSAPP TRIAL AT 6 YEARS

E. Herting, Lübeck, Germany

COFFEE BREAK

Chairpersons:
Mikko Hallman, Oulu, Finland
Ola D. Saugstad, Oslo, Norway

THE GENETIC BASIS OF SURFACTANT METABOLISM DISORDERS: TOWARDS PER-SONALIZED THERAPIES

Olivier Danhaive, Brussels, Belgium

USING EXPERIMENTAL MODELS TO IDENTIFY PATHOGENIC PATHWAYS AND PUTATIVE DISEASE MANAGEMENT TARGETS IN BRONCHOPULMONARY DYSPLASIA

Rory Morty, Bad Nauheim, Germany

Discussion

FREE COMMUNICATIONS

BRONCHOPULMONARY DYSPLASIA (BPD): DEVELOPMENT OF A PREDICTIVE SCORING SYSTEM FOR VERY LOW BIRTH WEIGHT INFANTS - THE SWISS-BPD-RISK SCORE

I. El Faleh, Lausanne, Switzerland

DOES RESIDENT ALVEOLAR TYPE 2 STEM CELL DEFECTS UNDERLIE PATHOGENE-SIS OF BPD?

P. Minoo, Los Angeles, United States

Adjourn

Chairpersons:
Dominique Haumont, Brussels, Belgium
Kris Sekar, Oklahoma City, United States

SPECIAL LECTURE HAZARDS OF PERIPARTUM ANTIBIOTICS BEYOND RESISTANCE

Alison Bedford-Russell, Birmingham, United Kingdom

NEONATAL NOSOCOMIAL SEPSIS: THE DAMOCLES SWORD CONTINUES TO SWING

Christian P. Speer, Würzburg, Germany

UPDATE ON NECROTIZING ENTEROCOLITIS

Josef Neu, Gainesville, United States

Discussion

COFFEE BREAK

Chairpersons:
Giuseppe Buonocore, Siena, Italy
Henry L. Halliday, Belfast, United Kingdom

NOVEL PHARMACODYNAMIC ACTIONS OF CAFFEINE IN NEWBORNS AND ONGOING CONTROVERSIES

Jacob Aranda, New York, United States

FREE COMMUNICATIONS

PROTECTIVE EFFECTS OF AMNIOTIC FLUID ON NECROTISING ENTEROCOLITIS IN AN EXPERIMENTAL MODEL: A BIOCHEMICAL, HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY

S. Takci, Tokat, Turkey

EARLY ONSET NEONATAL SEPSIS IN AFRICA - ALARMING RESULTS FROM A SYSTEMATIC REVIEW AND METANALYSIS

F. R. Mangeret, Geneva, Switzerland

MICROORGANISM PROFILE & ANTIMICROBIAL RESISTANCE PATTERN IN NEO-NATAL SEPSIS OVER 6 YEARS: EXPERIENCE FROM TERTIARY CARE HOSPITAL IN INDIA

S. Goel, New Dehli, India

Discussion

LUNCH

POSTER PRESENTATIONS

Chairpersons:
David Sweet, Belfast, United Kingdom
Maximo Vento, Valencia, Spain

STRICT EVALUATION OF CLINICAL SIGNS IS MORE ACCURATE THAN A MULTI-VARIATE RISK ASSESSMENT TO REDUCE THE RATE OF ANTIBIOTIC USE IN NEW-BORNS AT RISK OF NEONATAL EARLY-ONSET SEPSIS

R. S. Procianoy, Porto Alegre, Brazil

IMPLEMENTING PULSED XENON ULTRAVIOLET DISINFECTION IN A NEONATAL ICU AND ITS IMPACT ON NOSOCOMIAL SEPSIS

R. Dippenaar, Cape Town, South Africa

PREDICTIVE VALUE OF ‘SIGNS AND SYMPTOMS’ IN DIAGNOSIS OF CULTURE PROVEN EARLY ONSET NEONATAL SEPSIS (EONS) IN PRETERM NEONATES

S. Nangia, New Delhi, India

THE EFFECTS OF REDOX MODULATION ON IMMATURE NEURONS AND ERK1/2, AKT AND P38 SIGNALING PATHWAYS

D. Engur, Izmir, Turkey

POSSIBLE ANTIAPOPTOTIC AND NEUROPROTECTIVE EFFECTS OF MAGNESIUM SULPHATE ON RETINA IN A PRETERM HYPOXIC-ISCHEMIC RAT MODEL

F. Ovalı, Istanbul, Turkey

Chairpersons:
Eren Özek, Istanbul, Turkey
Elie Saliba, Paris, France

HOW FETAL STRESSES AND ANTENATAL MANAGEMENT MAY CONTRIBUTE TO NEONATAL TREATMENT REQUIREMENTS AND OUTCOME

Mikko Hallman, Oulu, Finland

IMPROVING SURVIVAL, IMPROVING OUTCOMES FOR NEONATES?

Neil Marlow, London, United Kingdom

Discussion

COFFEE BREAK

FREE COMMUNICATIONS

Chairpersons:
Umberto Simeoni, Lausanne, Switzerland
Ben Stenson, Edinburgh, United Kingdom

SETTING-UP OF A CLINICAL-LIKE INTENSIVE CARE PROTOCOL FOR ACUTE MANAGEMENT OF 27-DAY GESTATIONAL AGE RABBIT PUPS TO ACHIEVE LONG TERM SURVIVAL

C. Catozzi, Parma, Italy

MINIMAL INTERVENTION FOR EXTREMELY LOW GESTATION NEONATES IN THE FIRST 3 DAYS

I. Callander, Sydney, Australia

INTRAVENOUS ACETAMINOPHEN FOR THE NEWBORN: NO ADVERSE EFFECTS DURING THE FIRST FIVE YEARS

O. Aikio, Oulu, Finland

Discussion

CLOSING REMARKS

Scientific Committee